Report me for selling fake medicine? Why are you crying when your illness relapses?

Chen Xuan spoke slowly and gave an example.

This is a drug that has dominated for many years. Although it is not a drug of the same type, it is comparable.

The sales volume of 1500 billion US dollars has made it a legend among legends and it remains a myth to this day.

"And Humira, known as the "Ten-Year King of Medicines."

"Xiu Mei Yue has generated a total sales revenue of $2100 billion, and after 21 years, it still generated $241 billion to successfully defend the title."

"Even though Xiumeiyue is now nearing the end of its life cycle, its total sales are still expected to exceed $2500 billion."

"As for the new drug king, Keytruda, which was approved for marketing in 2014, its cumulative sales have already exceeded $100 billion for the first time. In 2013, it reached the top spot globally with sales of $28 billion."

When talking about the last medicine, Chen Xuan also emphasized his tone.

Although Keytruda's total sales are still far behind those of Lijinto and Xiumeiyue, it is still young and has just reached the top, and there is still endless potential.

As for the first two drugs, they have already passed their peak sales cycle and are now on a downward trend. Their annual sales will become less and less. Only Keytruda represents the future global drug king and has huge potential.

The reason why Chen Xuan mentioned it is because it is also an anti-cancer drug.

"Keytruda is also an anti-cancer drug. Its main indication is advanced melanoma, and it is also suitable for the treatment of some cancers."

"These indications make Keytruda a widely used anti-cancer drug. It can be used in conjunction with chemotherapy to achieve therapeutic effects, which is why it has such high sales."

"The lung cancer drug is also an anti-cancer drug. It is suitable for a wider range of patients and has indications for many other cancers besides lung cancer. It has a wider range of indications than Keytruda, and the market will only be larger than Keytruda."

Chen Xuan said directly, "Keytruda can break through $1000 billion in sales, and the lung cancer specific drug will break through $1000 billion even faster than Keytruda, and there will be no competitors for a long time."

As soon as these words came out, everyone was stunned.

Compared with Keytruda, the lung cancer specific drug does have greater advantages.

Although Keytruda is not used to treat lung cancer, they are both anti-cancer drugs and have many similarities.

In terms of treatment, specific drugs for lung cancer can directly treat lung cancer without the need for chemotherapy. They also have a restraining effect on some cancers and can prevent the disease from worsening.

In terms of the range of indications and effects, lung cancer specific drugs far exceed Keytruda, and not just by a little bit.

In this way, Keytruda can exceed 100 billion US dollars and become the world's leading drug.

The lung cancer drug will have the same potential and is indeed more likely to break through $1000 billion in sales faster.

"Hiss, now that Chen Xuan mentioned it, I don't think it's a problem."

"It is indeed very likely that the market value of lung cancer drugs will exceed $1000 billion, but it is only a possibility."

“Even if it can break through $1000 billion, pharmaceutical companies can’t just make a $1000 billion acquisition. They need a return.”

"If you spend $100 billion to acquire patents, then sales must reach at least $150 billion, or $200 billion to be suitable for investment."

"Yes, this will take at least ten years. If the returns are not big enough, it would be better to use the funds elsewhere."

"Chen Xuan didn't say he had to sell it. He just wanted $1000 billion to buy it from him. Essentially, he didn't want to sell it."

"The lung cancer drug created a sales myth of over 500 billion yuan upon its launch. I guess the giants are ready to make another move. If he doesn't ask for too much, how can he scare them away?"